期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Secure Key Management Based Mobile Authentication in Cloud
1
作者 S.Shanmuga Priya D.Yuvaraj +4 位作者 T.Satyanarayana Murthy Varghese S.Chooralil S.Navaneetha Krishnan P.Banumathy P.SundaraVadivel 《Computer Systems Science & Engineering》 SCIE EI 2022年第12期887-896,共10页
Authentication is important to the security of user data in a mobilecloud environment. Because of the server’s user credentials, it is subject toattacks. To maintain data authentication, a novel authentication mechan... Authentication is important to the security of user data in a mobilecloud environment. Because of the server’s user credentials, it is subject toattacks. To maintain data authentication, a novel authentication mechanism is proposed. It consists of three independent phases: Registration, login, and authentication and key agreement. The user registers with the Registration Center (RC)by producing a secret number that isn’t stored in the phone, which protects againstprivileged insider attacks. The user and server generate a nonce for dynamic useridentity and agree on a session secret key for safe communication. The passwordsare not stored on the computer or provided in plain text, they are resistant toreplay, guessing, and stolen verification attacks. The suggested protocol uses aone-way hash function and XOR operations, with the client having remote accessto a large number of servers over a secure communication channel. Concentrateson HMAC and SHA3 for Collision Free Hashing and to overcome length extension attacks. HMACs are substantially less affected by collisions than their underlying hashing algorithms alone. So adding an HMAC to an MD5 or SHA hashwould make it substantially more difficult to break via a rainbow table. 展开更多
关键词 registration center SIM IMEI
下载PDF
Safety and efficacy of intraperitoneal perfusion with tumor vesicle-encapsulated methotrexate for the treatment of cancerous ascites - an open, randomized and controlled clinical trial
2
作者 He Zhang Jing-Yi Zhang +3 位作者 Jing-Bo Zhai Hong-Bo Zhang Yi Lou Li-Zhu Shan 《TMR Non-Drug Therapy》 2020年第4期175-184,共10页
Background:Cancerous ascites is a common and severe complication that occurs in patients with late-stage malignant tumors.The prognosis of cancerous ascites is poor,clinical treatment is difficult and therapeutic outc... Background:Cancerous ascites is a common and severe complication that occurs in patients with late-stage malignant tumors.The prognosis of cancerous ascites is poor,clinical treatment is difficult and therapeutic outcome is disappointing.In the present study,tumor cell-derived vesicles were used as drug delivery vehicles that encapsulated a chemotherapeutic agent and were perfused into a patients’abdominal cavity to effectively kill the cancer cells in cancerous ascites.Pre-clinical data has demonstrated that tumor vesicles that carry low-dose chemotherapeutics can efficiently eliminate metastatic tumor cells in the abdominal cavity with minimal toxic or adverse effects.When combined,tumor cell-derived vesicles can sensitize tumor cells,which facilitates the entry of chemotherapeutics into tumor cells,thereby enhancing killing of tumor cells and limiting the risk of drug resistance.In this study,we designed a clinical trial to evaluate the safety and efficacy of intraperitoneal perfusion with tumor vesicle-encapsulated methotrexate for the treatment of cancerous ascites.Methods:Sixty patients with cancerous ascites were enrolled in this open,randomized and controlled clinical trial.Participants were randomly assigned a visit number and,according to their visiting order for which a random numerical table was used,were assigned to the trial group or the control group in a 1:1 ratio.The change in ascetic volume was used as the study outcome and adverse events were monitored during the entire length of the study.Conclusion:In this clinical trial,randomization and electronic case report forms were implemented.The trial indicated that tumor vesicle-encapsulated methotrexate was proposed to be a safe and effective method for treating malignant ascites.Our study may provide at the first time evidence for the clinical application of tumor vesicles in tumor therapy. 展开更多
关键词 Cancerous ascites EFFICACY Random and controlled trial Tumor vesicle Safety Clinical trial registration number:ChiCTR-IIR-16007842(China Clinical Trial registration center)
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部